Butylated Hydroxyanisole vs Aspartame: which is worse?

What is Butylated Hydroxyanisole?

Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum. It is a mixture of two isomeric compounds (2-BHA and 3-BHA). BHA prevents fats and oils from oxidizing (going rancid), extending shelf life. Its chemical formula is C11H16O2.

What is Aspartame?

Aspartame is a low-calorie synthetic dipeptide sweetener composed of two amino acids — phenylalanine and aspartic acid — bonded with methanol. When metabolized, it breaks down into these three components. It is approximately 200 times sweeter than sucrose, so tiny amounts provide significant sweetness with almost no calories.

Documented risks

Butylated Hydroxyanisole: BHA is classified by the International Agency for Research on Cancer (IARC) as Group 2B (possible human carcinogen) based on studies showing it causes papillomas and squamous cell carcinomas of the forestomach in rats, hamsters, and mice at high doses. A 1983 NTP bioassay confirmed these findings. The National Toxicology Program lists BHA as 'reasonably anticipated to be a human carcinogen' in its Report on Carcinogens. The forestomach is an anatomical structure found in rodents but not humans, creating some uncertainty about direct extrapolation. EFSA's 2012 re-evaluation (EFSA Journal 2012;10(10):2588) concluded that BHA may have endocrine-disrupting potential based on animal data showing interactions with estrogen receptors and androgenic hormone pathways. EFSA found the ADI of 1 mg/kg body weight but noted concerns about endocrine effects. Japan banned BHA for use in foods containing fats and oils, consistent with its generally precautionary approach to synthetic food preservatives. In cosmetics, the EU Scientific Committee on Consumer Safety (SCCS) has assessed BHA and found potential endocrine-disrupting effects at dermal exposure levels. EWG rates BHA as high-concern in Skin Deep cosmetics database. The antioxidant paradox applies: while BHA prevents lipid oxidation in foods, it may paradoxically act as a pro-oxidant in certain biological contexts at certain doses.

Aspartame: Aspartame has been one of the most studied food additives in history, with over 200 regulatory studies reviewed by multiple agencies. The FDA and EFSA have repeatedly reaffirmed its safety at permitted levels for the general population. IARC classification controversy (2023): In July 2023, IARC classified aspartame as Group 2B (possibly carcinogenic to humans), based primarily on limited evidence from human epidemiological studies associating aspartame intake with hepatocellular carcinoma (liver cancer) in some observational studies. Notably, the WHO Joint Expert Committee on Food Additives (JECFA) simultaneously re-evaluated aspartame and maintained the ADI at 40 mg/kg/day, concluding that the evidence does not establish that aspartame causes cancer at typical intake levels. This rare split between IARC (hazard identification) and JECFA (risk assessment) created significant public confusion. Phenylketonuria (PKU): Aspartame is definitively harmful for individuals with phenylketonuria — a genetic disorder affecting phenylalanine metabolism. People with PKU cannot process phenylalanine normally, and aspartame consumption can cause severe neurological damage. This is why all aspartame-containing products must carry a PKU warning on US and EU labels. Methanol release: aspartame metabolism releases methanol (~10% by weight). Critics including independent researcher Woodrow Monte have argued that methanol from aspartame is harmful, citing methanol's conversion to formaldehyde and formic acid in the body. However, methanol released from aspartame is a fraction of the methanol obtained from fresh fruit juices, and regulatory agencies consider the amounts released too small to be clinically significant. Gut microbiome concerns: a 2021 Cell study found that aspartame and other sweeteners altered gut microbiome composition and glucose tolerance in humans. These microbiome effects are an emerging area of research.